WO2022079439A3 - Novel trypanosomal vaccine - Google Patents

Novel trypanosomal vaccine Download PDF

Info

Publication number
WO2022079439A3
WO2022079439A3 PCT/GB2021/052666 GB2021052666W WO2022079439A3 WO 2022079439 A3 WO2022079439 A3 WO 2022079439A3 GB 2021052666 W GB2021052666 W GB 2021052666W WO 2022079439 A3 WO2022079439 A3 WO 2022079439A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
trypanosomal
novel
administering
infection
Prior art date
Application number
PCT/GB2021/052666
Other languages
French (fr)
Other versions
WO2022079439A2 (en
Inventor
Gavin Wright
Delphine AUTHEMAN
Original Assignee
Genome Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genome Research Limited filed Critical Genome Research Limited
Priority to GB2306884.4A priority Critical patent/GB2615687A/en
Priority to US18/249,030 priority patent/US20240050545A1/en
Publication of WO2022079439A2 publication Critical patent/WO2022079439A2/en
Publication of WO2022079439A3 publication Critical patent/WO2022079439A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a trypanosomal vaccine comprising an FLA1 binding protein, as well as to pharmaceutical compositions comprising said vaccine and their uses in vaccination to prevent or treat trypanosomal infection in a mammal. Thus, also provided are a method of preventing or treating trypanosomal infection comprising administering said vaccine and a kit of parts comprising a medical instrument or other means for administering.
PCT/GB2021/052666 2020-10-14 2021-10-14 Novel trypanosomal vaccine WO2022079439A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2306884.4A GB2615687A (en) 2020-10-14 2021-10-14 Novel trypanosomal vaccine
US18/249,030 US20240050545A1 (en) 2020-10-14 2021-10-14 Novel trypanosomal vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2016270.7A GB202016270D0 (en) 2020-10-14 2020-10-14 Novel trypanosomal vaccine
GB2016270.7 2020-10-14

Publications (2)

Publication Number Publication Date
WO2022079439A2 WO2022079439A2 (en) 2022-04-21
WO2022079439A3 true WO2022079439A3 (en) 2022-05-27

Family

ID=73460484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/052666 WO2022079439A2 (en) 2020-10-14 2021-10-14 Novel trypanosomal vaccine

Country Status (3)

Country Link
US (1) US20240050545A1 (en)
GB (2) GB202016270D0 (en)
WO (1) WO2022079439A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144465A1 (en) * 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144465A1 (en) * 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. P. JACKSON ET AL: "Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 9, 13 February 2012 (2012-02-13), pages 3416 - 3421, XP055398575, ISSN: 0027-8424, DOI: 10.1073/pnas.1117313109 *
AUTHEMAN DELPHINE ET AL: "An invariant Trypanosoma vivax vaccine antigen induces protective immunity", NATURE, vol. 595, no. 7865, 1 July 2021 (2021-07-01), London, pages 96 - 100, XP055891374, ISSN: 0028-0836, Retrieved from the Internet <URL:https://www.nature.com/articles/s41586-021-03597-x.pdf> DOI: 10.1038/s41586-021-03597-x *
DATABASE UniProt [online] 19 October 2011 (2011-10-19), "SubName: Full=WGS project CAEQ00000000 data, annotated contig 1422 {ECO:0000313|EMBL:CCD12653.1};", retrieved from EBI accession no. UNIPROT:F9W650 Database accession no. F9W650 *

Also Published As

Publication number Publication date
GB202016270D0 (en) 2020-11-25
US20240050545A1 (en) 2024-02-15
WO2022079439A2 (en) 2022-04-21
GB2615687A (en) 2023-08-16
GB202306884D0 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
EP2351767A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
MXPA05011110A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
WO2018033254A3 (en) Rna for cancer therapy
MX2009006760A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
BRPI0515520A (en) immunogenic composition, vaccine, methods of preparing a vaccine and preventing or treating staph infection, and use of immunogenic composition
MX2009005279A (en) N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer&#39;s.
ATE535252T1 (en) PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ALZHEIMER&#39;S DISEASE
EP1975235A3 (en) Porcine circovirus vaccine in recombinant poxvirus
MX2022010175A (en) Flt3 binding proteins and methods of use.
WO2019032936A8 (en) Lincosamide antibiotics and uses thereof
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
NO20070665L (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2022106897A3 (en) Methods and composition for kras modifications
WO2021158755A3 (en) Leptospiral proteins and uses thereof
ZA202110285B (en) Antibodies and methods of use
WO2022079439A3 (en) Novel trypanosomal vaccine
MX2022002437A (en) Methods for production of human recombinant arginase 1 and uses thereof.
MX2022000433A (en) Fusion toxin proteins for treatment of diseases related to cmv infections.
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
WO2022084355A3 (en) Agonistic trkb binding molecules for the treatment of eye diseases
EA200601392A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY
MX2023006294A (en) Il-7 binding proteins and their use in medical therapy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21823987

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023006906

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 202306884

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20211014

ENP Entry into the national phase

Ref document number: 112023006906

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230413

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21823987

Country of ref document: EP

Kind code of ref document: A2